Fabusiwa, K.
2  results:
Search for persons X
?
1

Safety in numbers: risankizumab for moderate‐to‐severe psor..:

Mirali, S. ; Fabusiwa, K. ; Linos, E.
British Journal of Dermatology.  186 (2022)  3 - p. 394-395 , 2022
 
1-2